• CE3 COMPARATIVE EFFECTIVENESS AMONG SINGLE AGENT CHEMOTHERAPEUTICS IN THE TREATMENT OF TNBC USING TIME TO NEXT TREATMENT AS A SURROGATE FOR EFFICACY

    Nov 1, 2019, 00:00

  • PMU113 IS THERE AN ASSOCIATION BETWEEN ERG AND NICE REIMBURSEMENT RECOMMENDATIONS?

    Nov 1, 2019, 00:00

  • PNS385 USING THE VARK MODEL TO AID QUALITATIVE DATA COLLECTION IN PEDIATRIC PATIENTS

    Nov 1, 2019, 00:00

  • PNS382 ACCURACY OF PRO DATA SIGNIFICANTLY IMPROVES WITH SUBJECT TRAINING IN MIGRAINE CLINICAL TRIALS

    Nov 1, 2019, 00:00

  • PNS136 MEDICAL DEVICES PRICE SETTING IN FRANCE: A RETROSPECTIVE ANALYSIS (2018-2019)

    Nov 1, 2019, 00:00

  • PDB94 PREDICTIVE MODELS USING MACHINE LEARNING FOR MICROVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 1 DIABETES: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PNS106 FACTORS AFFECTING THE HEALTHCARE PROVIDERS KNOWLEDGE OF PROJECT MANAGEMENT

    Nov 1, 2019, 00:00

  • PMH36 ST. JOHN'S WORT THERAPY IS ASSOCIATED WITH A REDUCED INCIDENCE OF DEMENTIA IN PATIENTS TREATED IN GENERAL PRACTICES

    Nov 1, 2019, 00:00

  • PCN136 ECONOMIC VIABILITY OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR ADULTS WITH ADVANCED LEUKEMIA: EVIDENCE FROM AN EARLY ECONOMIC MODELLING

    Nov 1, 2019, 00:00

  • PCN470 EXPERT CONSENSUS ON PATIENT-REPORTED OUTCOMES FOR THE MANAGEMENT OF PANCREATIC CANCER

    Nov 1, 2019, 00:00

  • PDG65 THE IMPACT OF OUT-OF-POCKET SPENDING ON THE PENETRATION OF GENERIC DRUGS AFTER THE EXPIRY OF THE MARKET EXCLUSIVITY

    Nov 1, 2019, 00:00

  • PNS62 HEALTH ECONOMIC VALUE OF BLOOD IN GHANA: THE CASE OF MATERNAL BLEEDING

    Nov 1, 2019, 00:00

  • PIH35 RATES OF DELIVERY WITH COMPLICATING CONDITIONS AND POSTPARTUM COMPLICATION RATES FOLLOWING DELIVERY SURGE AMONG U.S. MOTHERS

    Nov 1, 2019, 00:00

  • PNS402 PERCEIVED BARRIERS TO ENSURING THE EFFECTIVE UPTAKE OF PHARMACEUTICAL PRODUCTS BY PATIENTS

    Nov 1, 2019, 00:00

  • PIN37 HEALTH AND ECONOMIC BURDEN ASSOCIATED WITH 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE SEROTYPES IN CHILDREN IN THREE EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • Multiple Diseases - Medical Technologies

    Nov 1, 2019, 00:00

  • PNS225 CURRENT STATUS OF OUTCOMES-BASED AGREEMENTS IN SELECTED EUROPEAN COUNTRIES AND CANADA

    Nov 1, 2019, 00:00

  • PIH42 HEALTHCARE RESOURCE USE FOR THE MANAGEMENT OF POSTPARTUM HAEMORRHAGE IN FRANCE, ITALY, THE NETHERLANDS, AND THE UK

    Nov 1, 2019, 00:00

  • PND131 HOW WELL ARE MULTIPLE SCLEROSIS PATIENTS INFORMED ABOUT THEIR DISEASE AND THEIR TREATMENT: AN ANALYSIS OF DATA COLLECTED BY A NOVEL MOBILE APPLICATION (MS GEMEINSAM)

    Nov 1, 2019, 00:00

  • Surgery - Organizational Practices

    Nov 1, 2019, 00:00

  • PCN119 BUDGET IMPACT OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN BRAZIL

    Nov 1, 2019, 00:00

  • PMD54 MEDICAL CAPITAL EQUIPMENT TENDER ANALYTICS: META ANALYSIS ON WIN/LOSS STUDIES

    Nov 1, 2019, 00:00

  • PNS155 ACCESS OF BULGARIAN PATIENTS TO BIOSIMILAR MEDICINES

    Nov 1, 2019, 00:00

  • PCN515 A SURVEY OF CLINICAL PRACTICE FOR THE FRONTLINE TREATMENT OF PERIPHERAL T-CELL LYMPHOMA (PTCL) IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PNS156 CHANGES IN LEADING CAUSES OF DEATHS AND THE NUMBER OF HOSPITAL BEDS IN HUNGARY BETWEEN 2002 AND 2017

    Nov 1, 2019, 00:00

  • PMU110 OPTIMIZING EARLY ACCESS THROUGH ITALY'S PHARMACEUTICAL INNOVATION SYSTEM: KEY SUCCESS FACTORS FOR ATTAINING INNOVATIVE AND CONDITIONALLY INNOVATIVE STATUS

    Nov 1, 2019, 00:00

  • Cancer - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PND83 ACCESS TO INTRAVENOUS TISSUE-LIKE PLASMINOGEN ACTIVATOR (IV TPA) THERAPY AND MECHANICAL THROMBECTOMY (MT) FOR PATIENTS WITH ACUTE ISCHEMIC STROKE IN HUNGARY

    Nov 1, 2019, 00:00

  • PGI42 THE NEW WAVE OF ULCERATIVE COLITIS BIOLOGICS: CONSTRAINED BY THE COST-CONSCIOUS EUROPEAN MARKETS OR CHALLENGING THE TREATMENT PARADIGM?

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PMS29 HEALTH STATE UTILITY VALUES FOR JUVENILE IDIOPATHIC ARTHRITIS: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PMD23 BUDGET IMPACT ANALYSIS OF A BIOSYNTHETIC MESH FOR ABDOMINAL WALL HERNIA REPAIR IN COMPLEX HERNIAS IN GREECE

    Nov 1, 2019, 00:00

  • PDB36 EVALUATING THE IMPACT OF INSULIN PRICE FLUCTUATION IN THE USA ON THE HEALTHCARE EXPENDITURE IN T2DM

    Nov 1, 2019, 00:00

  • PMS10 COMPARATIVE ANALYSIS OF HIP PROSTHESIS BY REVISION METHODS FOR LATERAL AND DIRECT ANTERIOR APPROACH

    Nov 1, 2019, 00:00

  • PMU77 OPIOID USE PATTERNS AND HEALTHCARE USE AMONG INDIVIDUALS WITH COMORBID CHRONIC NON-CANCER PAIN AND OBSTRUCTIVE SLEEP APNEA

    Nov 1, 2019, 00:00

  • PNS37 SHOULD WE CONSTANTLY BE COUNTING WITH CONSTANT DISCOUNTING?

    Nov 1, 2019, 00:00

  • PMU73 MONETIZATION OF ADDITIONAL BENEFIT OF ORPHAN DRUGS IN GERMAN ARBITRATION BOARD DECISIONS

    Nov 1, 2019, 00:00

  • PDG45 5 YEAR STATUS OF RISK SHARING AGREEMENT IN KOREA SINCE THE IMPLEMENTATION

    Nov 1, 2019, 00:00

  • PMS32 COST MINIMIZATION ANALYSIS OF ZENTIUS FOR THE TREATMENT OF VITAMIN D AND CALCIUM DEFICIENCY IN TURKEY

    Nov 1, 2019, 00:00

  • PCN19 RELATIONSHIP OF STATIN OR ANTI PLATELET AGENTS AND HEPATOCELLULAR CARCINOMA IN TREATMENT NAIVE PATIENTS WITH CHB

    Nov 1, 2019, 00:00

  • PUK8 THE ECONOMIC IMPACT AND VARIABILITY OF MANAGING DISTRAL RENAL TUBULAR ACIDOSIS (DRTA) IN THE UK HEALTHCARE SETTING

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PIH26 JUVENILE IDIOPATHIC ARTHRITIS IS ASSOCIATED WITH CONSIDERABLE FINANCIAL BURDEN TO SOCIETY: RESULTS OF A DUTCH COST ANALYSIS

    Nov 1, 2019, 00:00

  • PMU112 ADHERENCE: NUDGING INNOVATION OF OUTCOMES-BASED CONTRACTS TO REWARD BEHAVIOR

    Nov 1, 2019, 00:00

  • PNS212 AIFA'S NEW INNOVATIVENESS DESIGNATION: DRIVERS FOR AWARD AND COMPARISON TO FRENCH HTA ASSESSMENTS

    Nov 1, 2019, 00:00

  • PGI47 PSYCHOMETRIC VALIDATION OF THE INTESTINAL GAS QUESTIONNAIRE (IGQ) FOR MEASURING GAS RELATED SYMPTOMS AND THEIR IMPACT ON DAILY LIFE

    Nov 1, 2019, 00:00

  • PMD16 HEALTH ECONOMIC VALUE OF BLOOD IN IVORY COAST: THE CASE OF MATERNAL BLEEDING

    Nov 1, 2019, 00:00

  • PMH39 CHARACTERISTICS OF US ADULTS WITH SELF-REPORTED INSOMNIA BY INSOMNIA SYMPTOMS: 2018 NATIONAL SLEEP SURVEY

    Nov 1, 2019, 00:00

  • PCN213 COST-UTILITY ANALYSIS OF ABIRATERONE IN THE TREATMENT OF DOCETAXEL-REFRACTORY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER COMPARED TO BEST SUPPORTIVE CARE IN IRAN

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PCN152 COST-UTILITY AUC MODEL ADAPTED TO ITALIAN CLINICAL PRACTICE FOR EVALUATION OF ENTRECTINIB VERSUS STANDARD OF CARE IN ROS1+ NSCLC PATIENTS

    Nov 1, 2019, 00:00

  • PIN93 REAL WORLD DATA EXAMINING THE EFFECT OF DIRECT ACTING ANTIVIRALS AMONG PATIENTS DEFINED BY FIBROSIS STAGE AND VIRAL LOAD

    Nov 1, 2019, 00:00

  • PMS2 EXAMINATION OF A SPORT-SPECIFIC DYNAMIC CORE STABILITY PROGRAMME AMONG FEMALE ACROBATIC ROCK AND ROLL DANCERS

    Nov 1, 2019, 00:00

  • PIH14 INCREMENTAL COSTS OF PREMATURITY AND LOW BIRTHWEIGHT

    Nov 1, 2019, 00:00

  • PIN75 WHAT WE KNOW NOW: REVISITING THE COST-EFFECTIVENESS OF CHICKENPOX VACCINATION USING AN AGENT-BASED MODEL

    Nov 1, 2019, 00:00

  • PCN432 EVALUATION OF MISSING DATA IMPUTATION STRATEGIES IN CLINICAL TRIAL AND EMR DATA USING STANDARDIZED DATA MODELS

    Nov 1, 2019, 00:00

  • PMH18 PREVENTING MENTAL HEALTH CONDITIONS IN CHILDREN AND YOUNG ADULTS: A REVIEW OF THE COSTS OF COMPLEX INTERVENTIONS

    Nov 1, 2019, 00:00

  • PDG71 A STUDY OF PHARMACIST'S LEVEL OF AWARENESS ABOUT FIRST REIMBURSEMENT PROGRAM IN UKRAINE

    Nov 1, 2019, 00:00

  • PCN189 COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB PLUS FULVESTRANT VERSUS EVEROLIMUS PLUS EXEMESTAN IN THE TREATMENT OF ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER IN IRAN

    Nov 1, 2019, 00:00

  • PGI29 AN ECONOMIC EVALUATION OF TOFACITINIB IN THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • CL2 SYSTEMATIC REVIEW AND METANALYSIS ON THE IMPACT OF MULTI-DRUG RESISTANT BACTERIA ON ECONOMIC AND CLINICAL OUTCOMES OF HEALTHCARE ACQUIRED INFECTIONS

    Nov 1, 2019, 00:00

  • Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions

    Nov 1, 2019, 00:00

  • CV4 HOSPITALIZED WITH STROKE AT THE WEEKEND: ARE THERE HIGHER RISK OF EARLY DEATH AND HIGHER COSTS?

    Nov 1, 2019, 00:00

  • PIH34 THE ASSOCIATION BETWEEN ANTICHOLINERGIC MEDICINE AND COGNITION DECLINE IN OLDER ADULTS: A SYSTEMIC REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00

  • PSY57 PATTERNS OF PHARMACOLOGICAL TREATMENT IN ADULT PATIENTS WITH ATOPIC DERMATITIS

    Nov 1, 2019, 00:00

  • PDG19 CHARACTERISTICS AND HEALTHCARE SERVICE USE OF PATIENTS WITH SCHIZOPHRENIA SWITCHING FROM ORAL TO LONG-ACTING INJECTABLE ANTIPSYCHOTICS

    Nov 1, 2019, 00:00

  • PNS75 PROPER INCORPORATION OF ADVERSE EVENTS FROM MEDICAL TREATMENTS (AEMT) IN HEALTH TECHOLOGY ASSESSMENTS (HTA)

    Nov 1, 2019, 00:00

  • PSY8 ECONOMIC EVALUATION OF GUSELKUMAB AND OTHER IL-INHIBITORS FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN ITALY

    Nov 1, 2019, 00:00

  • PND69 COSTS OF MULTIPLE SCLEROSIS IN DENMARK: INFORMAL CAREGIVER'S PERSPECTIVE

    Nov 1, 2019, 00:00

  • PND45 OCRELIZUMAB IS A COST-EFFECTIVE OPTION FOR RELAPSING MULTIPLE SCLEROSIS PATIENTS, IN IRAN

    Nov 1, 2019, 00:00

  • PCV71 INDIRECT COMPARISON OF NEUROPROTECTORS IN THE TREATMENT OF ISCHEMIC STROKE IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PDG10 IMPROVING THE BUSINESS MODEL OF VALUE ADDED MEDICINES: NEW VALUE ASSESSMENT FRAMEWORK IS NEEDED

    Nov 1, 2019, 00:00

  • Personalized Precision Medicine - Economic Evaluation

    Nov 1, 2019, 00:00

  • PNS379 SUFFERING ALONE: UNMET NEEDS FOR INFORMAL CARE IN HUNGARY, POLAND AND SLOVENIA

    Nov 1, 2019, 00:00

  • PRO149 PATIENT ENGAGEMENT IN RESEARCH: THE EURORDIS PATIENT-LED COMMUNITY ADVISORY BOARDS (CABS)

    Nov 1, 2019, 00:00

  • PCN62 COMPARISON OF NETWORK META-ANALYSES USING STANDARD, MIXTURE CURE AND SPLINE MODELS

    Nov 1, 2019, 00:00

  • PCV149 UNHEALTHY WEEKENDS OR MONDAY BLUES? INVESTIGATING THE WEEKLY PATTERN OF STROKES

    Nov 1, 2019, 00:00

  • PRO61 EPIDEMIOLOGY OF HEMOPHILIA IN GERMANY: RESULTS FROM A GERMAN STATUTORY HEALTH INSURANCE CLAIMS DATABASE-ANALYSIS

    Nov 1, 2019, 00:00

  • PCN471 ATTITUDE TOWARDS CERVICAL CANCER SCREENING ATTENDANCE AND NON-ATTENDANCE AMONG ROMANY AND NON-ROMANY WOMEN

    Nov 1, 2019, 00:00

  • PCN241 COSTS OF CYTOKINE RELEASE SYNDROME (CRS) AND NEUROLOGICAL EVENTS (NE) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA RECEIVING LISOCABTAGENE MARALEUCEL (LISO-CEL) IN THE TRANSCEND NHL 001 CLINICAL TRIAL: A MICRO-COSTING ST ...

    Nov 1, 2019, 00:00

  • PCN224 TREATMENT BENEFIT DISCONTINUATION: COMPARISON OF A PARTITIONED SURVIVAL ANALYSIS AND A SEMI-MARKOV MULTI-STATE MODEL APPROACH USING AN ONCOLOGY CASE STUDY

    Nov 1, 2019, 00:00

  • Individual's Health - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PCN166 ECONOMIC EVALUATION OF ANTICANCER DRUGS: A SYSTEMATIC REVIEW ON COST-EFFECTIVENESS STUDIES BASED ON HEALTHCARE SYSTEM CLAIMS DATABASES

    Nov 1, 2019, 00:00

  • PCN322 TREATMENT OF ADVANCED BILIARY TRACT CANCER (BTC) AFTER PROGRESSION ON FIRST-LINE (1L) SYSTEMIC THERAPY

    Nov 1, 2019, 00:00

  • PCV109 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS FOR THE MINIMALLY INVASIVE SUTURELESS AORTIC VALVE REPLACEMENT IN PATIENTS WITH AORTIC STENOSIS IN POLAND

    Nov 1, 2019, 00:00

  • PDG58 THE IMPACT OF ECONOMIC REGULATION ON EXPANSIVE DRUG LIST IN FRANCE BETWEEN 2008 AND 2018

    Nov 1, 2019, 00:00

  • PCV70 HEALTH CARE COST FOR PATIENTS WITH CHRONIC HEART FAILURE AND IRON DEFICIENCY / ANEMIA BEFORE AND AFTER TREATMENT WITH FERRIC CARBOXYMALTOSE

    Nov 1, 2019, 00:00

  • PDB68 ASSESSMENT OF RISK FOR DEVELOPMENT OF TYPE 2 DIABETES IN THE GREEK POPULATION

    Nov 1, 2019, 00:00

  • PRS54 THE SUITABILITY OF THE EQ-5D-5L IN ASTHMA PATIENTS

    Nov 1, 2019, 00:00

  • PCN390 ANALYSIS OF INDIRECT TREATMENT COMPARISONS IN ONCOLOGY-RELATED HTA DECISIONS IN GERMANY

    Nov 1, 2019, 00:00

  • PMU64 UNLOCKING ACCESS FOR TRANSFORMATIONAL CAR-T CELL AND GENE THERAPIES. ARE BIOSIMILARS THE KEY?

    Nov 1, 2019, 00:00

  • PDG22 THE ECONOMIC IMPACT OF SERIOUS FLUOROQUINOLONE-RELATED ADVERSE EVENTS

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PCV153 HOW COSTLY IS POOR ADHERENCE TO PHARMACOLOGICAL TREATMENTS FOR CARDIOVASCULAR DISEASE? A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • NO Specific Disease - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PND103 BURDEN OF COMORBID DEPRESSION AND ANXIETY ON WORK PRODUCTIVITY IN ADULT MIGRAINE PATIENTS IN THE UNITED STATES

    Nov 1, 2019, 00:00

  • PMS58 HEALTH TECHNOLOGY ASSESSMENT (HTA) OF EQUISTASI FOR THE TREATMENT OF PATIENTS WITH PARKINSONIAN POST-DYSKINESIA FALLS.

    Nov 1, 2019, 00:00

  • PCN311 OPTIMAL BREAST CANCER SCREENING POLICY STRATIFYING BY BREAST DENSITY

    Nov 1, 2019, 00:00

  • PCN122 COST-EFFECTIVENESS ANALYSIS OF TRASUTUZUMAB EMTANSINE VERSUS TRASTUZUMAB FOR WOMEN WITH HER2+ ADJUVANT BREAST CANCER IN FRANCE

    Nov 1, 2019, 00:00

  • PRO19 THE ROLE PLAYED BY SOCIAL COSTS IN ECONOMIC EVALUATIONS OF RARE DISEASE INTERVENTIONS

    Nov 1, 2019, 00:00

  • PCN158 PATIENT BURDEN AND COSTS FOR THE TREATMENT OF MULTIPLE MYELOMA IN FINLAND IN 2009-2016, USING MULTIPLE DATA SOURCES: AN ELECTRONIC HOSPITAL DATABASE, MEDICAL CHART REVIEW, AND INTERVIEWS WITH HEALTHCARE PROFESSIONALS

    Nov 1, 2019, 00:00

  • PCN45 PEMBROLIZUMAB PLUS AXITINIB (P+A) VERSUS OTHER FIRST-LINE (1L) SYSTEMIC THERAPIES FOR ADVANCED/METASTATIC CLEAR-CELL RENAL CELL CARCINOMA (CCMRCC) — A NETWORK META-ANALYSIS (NMA)

    Nov 1, 2019, 00:00

  • PNS346 CAN META-ANALYSES HELP IN SYNTHESIZING DATA ACROSS HEALTH ECONOMIC STUDIES?

    Nov 1, 2019, 00:00

  • PSY7 INDIRECT COST BURDEN OF MODERATE-TO-SEVERE PSORIASIS IN EU5 AND THE SAVINGS GENERATED BY CHOOSING GUSELKUMAB OVER ADALIMUMAB

    Nov 1, 2019, 00:00

  • PRS3 A SYSTEMATIC REVIEW OF SINGLE-INHALER TRIPLE THERAPY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Nov 1, 2019, 00:00

  • PCN154 INCORPORATING THE VALUE HEALTHY INDIVIDUALS PLACE ON GENEROUS INSURANCE COVERAGE OF SEVERE DISEASES: A STATED PREFERENCE SURVEY OF ADULT COHORTS WITH AND AT-RISK FOR LUNG CANCER

    Nov 1, 2019, 00:00

  • PDG26 COST-EFFECTIVENESS OF RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGICAL MYOPIA: FROM CHINESE SOCIETAL PERSPECTIVE

    Nov 1, 2019, 00:00

  • Surgery - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PUK11 TOLVAPTAN REDUCES HEALTHCARE BURDEN IN PATIENTS WITH STAGE 1-3 ADPKD IN SPAIN

    Nov 1, 2019, 00:00

  • PDB53 BUDGET IMPACT MODELLING OF POINT-OF-CARE HBA1C MONITORING OF PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS TYPE II IN RUSSIA

    Nov 1, 2019, 00:00

  • PCN29 COMPARATIVE EFFICACY OF NIVOLUMAB VERSUS RELEVANT TREATMENTS IN PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A SYSTEMATIC LITERATURE REVIEW AND INDIRECT TREATMENT COMPARISON OF RANDOMIZED CONTROLLED TRIALS (RCTS)

    Nov 1, 2019, 00:00

  • Individual's Health - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PBI27 BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE

    Nov 1, 2019, 00:00

  • PIH22 ESTIMATING THE PRODUCTIVITY BURDEN OF PEDIATRIC PNEUMOCOCCAL DISEASE IN THAILAND

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PDG62 THE CONTINUUM OF INTERNATIONAL REFERENCE PRICING USE IN LATIN AMERICA: A QUALITATIVE ANALYSIS

    Nov 1, 2019, 00:00

  • PCN7 THE VALUE OF OBINUTUZUMAB FOR UNTREATED ADVANCED FOLLICULAR LYMPHOMA: AN ASSESSMENT BASED ON MULTICRITERIA DECISION ANALYSIS (MCDA)

    Nov 1, 2019, 00:00

  • PDB128 A NATIONWIDE, OBSERVATIONAL STUDY ASSESSING ADHERENCE TO THE HELLENIC GUIDELINES FOR FOLLOW-UP, CLINICAL, AND LABORATORY EVALUATIONS, IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: THE GLANCE™ STUDY

    Nov 1, 2019, 00:00

  • PIH13 A COST-EFFECTIVENESS ANALYSIS OF ENTERAL LACTOFERRIN SUPPLEMENTATION FOR VERY PRETERM INFANTS: THE ELFIN TRIAL

    Nov 1, 2019, 00:00

  • PCN416 NETWORK META-ANALYSIS FOR SURROGATE ENDPOINT EVALUATION IN ADVANCED COLORECTAL CANCER: A BAYESIAN APPROACH

    Nov 1, 2019, 00:00

  • PDG23 BUDGET IMPACT ANALYSIS OF SOMATOSTATIN ANALOGUES IN THE TREATMENT OF GEP-NET AND ACROMEGALY IN THE UK

    Nov 1, 2019, 00:00

  • PMH57 IMPACT ON QUALITY OF LIFE AND PRODUCTIVITY FOR CAREGIVERS OF ADULTS WITH DEPRESSION

    Nov 1, 2019, 00:00

  • PBI54 BIOSIMILAR AND ORIGINATOR INFLIXIMAB AND ETANERCEPT: INFLUENCE OF LOCAL POLICY MEASURES AND PRACTICES ON MARKET DYNAMICS IN THE UK

    Nov 1, 2019, 00:00

  • PNS101 ASSOCIATION BETWEEN RISK FACTORS AND SAFE DRUG DISPOSAL IN COMMUNITY: A CROSS SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • Mental Health - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PDG4 TILDRAKIZUMAB VERSUS GUSELKUMAB: A BUCHER INDIRECT COMPARISON

    Nov 1, 2019, 00:00

  • PDG96 SURVEY ABOUT KNOWLEDGE OF NANOMEDICINES AMONG PHARMACISTS IN UKRAINE

    Nov 1, 2019, 00:00

  • PNS247 THE IMPLICATIONS OF EUROPEAN JOINT CLINICAL ASSESSMENT FOR MEMBER STATE PRICING MARKET ACCESS

    Nov 1, 2019, 00:00

  • PCN14 MATCHING-ADJUSTED INDIRECT COMPARISON OF ENTRECTINIB VERSUS CRIZOTINIB IN ROS1 NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PNS152 WILLINGNESS TO PAY FOR SOCIAL HEALTH INSURANCE AND RELATED FACTORS AMONG POPULATION IN YOGYAKARTA PROVINCE, INDONESIA

    Nov 1, 2019, 00:00

  • PRO88 PAYER AND PHYSICIAN PERSPECTIVES OF CURRENT AND EMERGING SPINAL MUSCULAR ATROPHY TREATMENTS IN THE EU5

    Nov 1, 2019, 00:00

  • PCV132 APPLYING EUROQOL-5D IN MIDDLE EASTERN PATIENTS WITH CARDIOVASCULAR DISEASES (CVD); A SAUDI PERSPECTIVE

    Nov 1, 2019, 00:00

  • PIN27 ECONOMIC AND QUALITY OF LIFE BURDEN OF PAEDIATRIC INFLUENZA IN AUSTRALIA

    Nov 1, 2019, 00:00

  • PCN397 INCORPORATING RISK SCORES IN CRC SCREENING MODELS: A EXAMPLE FROM THE INCA-PHE CRC MODEL

    Nov 1, 2019, 00:00

  • PCN514 REAL WORLD TREATMENT PATHWAYS OF DIFFUSE LARGE B-CELL LYMPHOMA IN GERMAN CLAIMS DATA

    Nov 1, 2019, 00:00

  • PRO92 AN ANALYSIS OF ORPHAN MEDICINES EXPENDITURE IN IRAN, 2018

    Nov 1, 2019, 00:00

  • PRO62 SYSTEMATIC LITERATURE REVIEW OF DISEASE BURDEN, COSTS AND MODELS IN TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)

    Nov 1, 2019, 00:00

  • PCN275 THE GLOBAL EPIDEMIOLOGY OF PERIPHERAL T-CELL LYMPHOMA: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PSY51 PSYCHOMETRIC PERFORMANCE OF PLAQUE PSORIASIS PATIENT REPORTED OUTCOME NUMERIC RATING SCALES IN A PHASE 2B CLINICAL TRIAL

    Nov 1, 2019, 00:00

  • PIH30 CHALLENGES FACED BY PEOPLE WITH PHYSICAL DISABILITIES IN ACCESSING SEXUAL AND REPRODUCTIVE HEALTH SERVICES IN EASTERN REGION OF NEPAL

    Nov 1, 2019, 00:00

  • PDB55 COST-EFFECTIVENESS ANALYSIS OF NONINVASIVE SCORES FOR THE SCREENING OF NON-ALCOHOLIC FATTY LIVER DISEASE AMONG METABOLIC SYNDROME PATIENTS

    Nov 1, 2019, 00:00

  • PMS5 THE EFFECT OF DANCE THERAPY ON DEVELOPMENT OF MOVEMENT IN CHILDREN WITH DOWN SYNDROME

    Nov 1, 2019, 00:00

  • PSS7 COMPARING TWO TREAT-AND-EXTEND ANTI-VEGF REGIMENS FOR MANAGING WET AGE-RELATED MACULAR DEGENERATION - IMPLICATIONS FOR THE NATIONAL HEALTH SYSTEM IN JAPAN

    Nov 1, 2019, 00:00

  • PMU41 THE ASSOCIATION BETWEEN MULTIMORBIDITY AND PERCEIVED WORKING CONDITIONS IN EUROPE

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PBI53 GENE THERAPY PREPAREDNESS IN EUROPE

    Nov 1, 2019, 00:00

  • PCV95 ANALYSIS OF ACE-INHIBITORS PRICES IN FOUR EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PCN323 CHANGE IN TREATMENT PARADIGM OF ALK+ NON-SMALL CELL LUNG CANCER (NSCLC) IN THE ITALIAN REAL PRACTICE

    Nov 1, 2019, 00:00

  • PCV120 A STATISTICAL COMPARISON OF LOGISTIC REGRESSION VERSUS MACHINE LEARNING TREE-BASED CLASSIFICATION METHODS IN PREDICTING CORONARY HEART DISEASE USING REAL-WORLD PATIENT-LEVEL DATA

    Nov 1, 2019, 00:00

  • CC3 COST-EFFECTIVENESS ANALYSIS OF VORETIGENE NEPARVOVEC VERSUS BEST SUPPORTIVE CARE IN PATIENTS WITH RPE65-MEDIATED INHERITED RETINAL DYSTROPHY: A FRENCH HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PNS312 QUANTITATIVE AND QUALITATIVE ANALYSIS OF THE AMNOG ARBITRATION BOARD DECISION FACTORS FOR THE PRICING OF NEW ACTIVE SUBSTANCES IN GERMANY

    Nov 1, 2019, 00:00

  • PNS381 THE RISE OF THE SOCIAL MEDIA MACHINE: A REVIEW OF PATIENT-CENTERED RESEARCH UTILIZING SOCIAL MEDIA RESEARCH METHODS PRESENTED AT ISPOR (2010 -2018)

    Nov 1, 2019, 00:00

  • PNS5 RELATIVE EFFECT OF INTERVENTIONS IN ACTINIC KERATOSIS: FINDINGS FROM METHODOLOGICAL ASSESSMENT AND NETWORK META-ANALYSES

    Nov 1, 2019, 00:00

  • PDB70 CHARACTERISTICS OF PATIENTS WITH TYPE 2 DIABETES MELLITUS NEWLY TREATED WITH BASAL INSULIN THERAPY: A POPULATION-BASED UK STUDY

    Nov 1, 2019, 00:00

  • PND3 IMPACT OF SOCIAL NETWORK INTERVENTIONS ON SCHIZOPHRENIA OUTCOMES

    Nov 1, 2019, 00:00

  • PMD34 FRENCH COVERAGE WITH EVIDENCE DEVELOPMENT (CED) SCHEME FOR INNOVATIVE MEDICAL DEVICES: AN OVERVIEW SINCE ITS REDESIGN IN 2015

    Nov 1, 2019, 00:00

  • PDB80 DIABETIC MACULAR EDEMA IN EUROPE: THE IMPACT OF PAYER POLICY ON PRESCRIBING

    Nov 1, 2019, 00:00

  • PCN488 A SYSTEMATIC LITERATURE REVIEW OF STUDIES REPORTING THE HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH METASTATIC PANCREATIC CANCER BEFORE OR AFTER TREATMENT

    Nov 1, 2019, 00:00

  • PMU38 COSTS-EFFECTIVITY, HEALTH ECONOMIC EVALUATION, SYSTEMATIC REVIEW AND METANALYSIS OF BARIATRIC SURGERY IN REDUCING OBESITY RELATED DISEASES, MORTALITY, DEPRESSION AND CANCER

    Nov 1, 2019, 00:00

  • PBI44 REAL-WORLD EVIDENCE IN GENE THERAPIES: RECOMMENDATIONS VERSUS REALITY

    Nov 1, 2019, 00:00

  • PRS59 ADAPTION OF THE ADHERENCE BARRIERS QUESTIONNAIRE (ABQ) FOR USE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Nov 1, 2019, 00:00

  • PUK32 PATIENT INSIGHTS FOR IMMUNOGLOBULIN A NEPHROPATHY (IGAN) USING SOCIAL MEDIA LISTENING

    Nov 1, 2019, 00:00

  • Infectious Diseases - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PCN108 NIVOLUMAB-ADJUVANT THERAPY FOR RESECTED STAGE III-IV MELANOMA: A COST-EFFECTIVENESS ANALYSIS FOR SPAIN

    Nov 1, 2019, 00:00

  • PMU119 WHAT ARE THE KEY CHALLENGES ENCOUNTERED IN THE DESIGN, CONDUCT AND ASSESSMENT OF PRAGMATIC TRIALS AND HOW ARE THEY ADDRESSED?

    Nov 1, 2019, 00:00

  • AD4 ESTIMATING THE RELIABILITY OF THE MEDICATION ADHERENCE REASONS SCALE (MAR-SCALE) IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISORDER AND IDENTIFYING THE REASONS FOR NON-ADHERENCE

    Nov 1, 2019, 00:00

  • PDB65 PRETRIAL MODELLING METHODS TO JUSTIFY AND INFORM THE DESIGN OF LARGE RCTS - EXPECTED VALUE OF SAMPLE INFORMATION FOR THE DAFNEPLUS DIABETES EDUCATION CLUSTER RCT

    Nov 1, 2019, 00:00

  • PNS349 DEVELOPMENT OF PLAIN ENGLISH SUMMARIES OF HEALTH TECHNOLOGY ASSESSMENT (HTA) REPORTS IN THE NATIONAL CENTRE FOR PHARMACOECONOMICS (NCPE) IRELAND

    Nov 1, 2019, 00:00

  • PNS191 IMPLEMENTATION OF A NEW MODEL OF THE NURSING CARE MANAGEMENT IN THE REPUBLIC OF KAZAKHSTAN: POLICY BRIEF

    Nov 1, 2019, 00:00

  • PCN495 REAL WORLD STUDIES IN ONCO-HEMATOLOGY: WHICH PARAMETER SHOULD BE USED TO MEASURE THE EFFICACY OF TREATMENTS?

    Nov 1, 2019, 00:00

  • Stroke Warning Information and Faster Treatment (SWIFT): Cost-Effectiveness of a Stroke Preparedness Intervention

    Nov 1, 2019, 00:00

  • Cancer - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PCN24 TYROSINE KINASE INHIBITORS: REAL WORLD EVIDENCE ABOUT HEALTH OUTCOMES IN A MIDDLE INCOME COUNTRY

    Nov 1, 2019, 00:00

  • PNS172 TRENDS IN PRESCRIPTION MONITORING PROGRAM PATIENT QUERIES AND DELEGATE ACCESS

    Nov 1, 2019, 00:00

  • PMH42 TARGETED LITERATURE REVIEW (TLR) OF THE ECONOMIC BURDEN OF COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS)

    Nov 1, 2019, 00:00

  • PNS398 THE ASSOCIATION BETWEEN EHEALTH-LITERACY, SHARED DECISION-MAKING AND HEALTH RISK BEHAVIOURS IN AN ONLINE SAMPLE OF THE HUNGARIAN GENERAL POPULATION

    Nov 1, 2019, 00:00

  • PMH68 IMPLEMENTING AND INTERPRETING A PROPOSED NEW MEASURE FOR HEDIS® 2020: PHARMACOTHERAPY FOR OPIOID USE DISORDER (OUD)

    Nov 1, 2019, 00:00

  • PBI77 PAYING FOR CURES: AN ANALYSIS OF INNOVATIVE ACCESS AGREEMENTS FOR LICENSED GENE THERAPIES

    Nov 1, 2019, 00:00

  • PNS297 CLINICAL AND KEY OPINION LEADERS VALIDATION IN HEALTH ECONOMICS MODEL AND COMPARATIVE EFFECTIVENESS: A GUIDE FOR NON-EXPERT AUDIENCE

    Nov 1, 2019, 00:00

  • PCN233 COST EFFECTIVENESS OF OBINUTUZUMAB PLUS BENDAMUSTINE VS BENDAMUSTINE ALONE FOR PATIENTS WHO DID NOT RESPOND OR PROGRESSED DURING OR AFTER RITUXIMAB OR A RITUXIMAB CONTAINING REGIMENT IN TURKEY

    Nov 1, 2019, 00:00

  • Neurological Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • Cannabis and Health Research: Rapid Progress Requires Innovative Research Designs [Editor's Choice]

    Nov 1, 2019, 00:00

  • PNS292 BUDGET IMPACT OF SOFTWARE SUPPORTING SAFE, EFFECTIVE AND EFFICIENT WORKING OF NHS ACUTE CARE PROVIDERS: ACTUAL BUDGET IMPACT FOR IMPLEMENTATION SITE AND LOST OPPORTUNITY SAVING AND PROJECTED BUDGET IMPACT POTENTIAL FOR OTHER SITES

    Nov 1, 2019, 00:00

  • PNS252 DO MARKET WITHDRAWALS IMPACT PATIENT ACCESS TO TREATMENT IN GERMANY?

    Nov 1, 2019, 00:00

  • PCN113 COST-MINIMISATION AND FIVE-YEAR BUDGET IMPACT ANALYSIS FOR MVASI® (BEVACIZUMAB BIOSIMILAR) IN ITALY

    Nov 1, 2019, 00:00

  • PNS270 ASSESSING THE PUBLIC HEALTH BENEFIT OF A MEDICINE: AN ANALYSIS OF THE CRITERIA APPRAISED BY THE FRENCH HTA BODY SINCE THE PUBLICATION OF ITS UPDATED MISSION STATEMENT OF SEPTEMBER 2018

    Nov 1, 2019, 00:00

  • PMU90 REVIEW OF PUBLISHED EFFICIENCY OPINIONS OF THE FRENCH ECONOMIC AND PUBLIC HEALTH ASSESSMENT COMMITTEE (CEESP)

    Nov 1, 2019, 00:00

  • PMD12 UNDERSTANDING THE ECONOMIC IMPACT OF THERAPEUTIC PLASMA EXCHANGE: A SINGLE INSTITUTION STUDY IN PUNE, INDIA

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PCV18 THE LONG-TERM EFFECTS OF MAINTAINING RAASI TREATMENT IN PATIENTS WITH HEART FAILURE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PMD21 ECONOMIC EVALUATION OF THE SFLT-1/PLGF RATIO TEST TO GUIDE THE MANAGEMENT OF CHINESE SUSPECTED PRE-ECLAMPSIA WOMEN

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PCV48 COST EFFECTIVENESS OF RIVAROXABAN IN CORONARY ARTERY DISEASE AND/OR PERIPHERAL ARTERY DISEASE FOR 5 DIFFEREN PATIENT SUB-GROUPS IN TURKEY

    Nov 1, 2019, 00:00

  • PNS125 SHOULD DRUG PRICES DIFFER BY INDICATION? RESULTS OF A CONSULTATION

    Nov 1, 2019, 00:00

  • PSY26 UNMET MEDICAL NEED OF PRURIGO NODULARIS

    Nov 1, 2019, 00:00

  • PMU136 PSYCHOMETRIC PROPERTIES OF MALE SEXUAL HEALTH QUESTIONNAIRE (MSHQ), IN HIV AND HCV PATIENTS

    Nov 1, 2019, 00:00

  • PUK27 THE ECONOMIC IMPACT OF DIGITAL HEALTH INTERVENTIONS IN THE MANAGEMENT OF TYPE 2 DIABETES: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PNS76 A BAYESIAN PARAMETRIC APPROACH TO HANDLE MISSING LONGITUDINAL OUTCOME DATA IN TRIAL-BASED HEALTH ECONOMIC EVALUATIONS

    Nov 1, 2019, 00:00

  • PIH43 CAN USING POINT OF CARE BLOOD TESTS HELP INFORM DECISION MAKING FOR PATIENTS WITH ACUTE FRAILTY SYNDROME? A BUDGET IMPACT ANALYSIS

    Nov 1, 2019, 00:00

  • PIN150 ANALYSIS OF TREATMENT SEQUENCES FROM THE FRENCH NATIONAL SNIIRAM DATABASE: CASE STUDY OF INCIDENT PEOPLE LIVING WITH HIV IN 2013

    Nov 1, 2019, 00:00

  • PMU28 CAVEATS IN COST-EFFECTIVENESS ANALYSIS OF REMOTE PATIENT MONITORING: IMPACT OF END-OF-LIFE ADJUSTMENT OF QALYS ON DECISION MAKING METRICS

    Nov 1, 2019, 00:00

  • PNS153 MOVING TOWARD UNIVERSAL HEALTH COVERAGE IN JORDAN

    Nov 1, 2019, 00:00

  • PSS21 EFFECT OF ISTENT INJECT TRABECULAR MICRO-BYPASS ON PATIENT-REPORTED OUTCOMES FOR THOSE WITH OPEN-ANGLE GLAUCOMA AND COEXISTING CATARACTS

    Nov 1, 2019, 00:00

  • PCN497 A NATIONWIDE COST OF ILLNESS STUDY OF METASTATIC CUTANEOUS MELANOMA IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PRO28 EMICIZUMAB PROPHYLAXIS IN HAEMOPHILIA A PATIENTS WITH INHIBITORS: A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS

    Nov 1, 2019, 00:00

  • PCN94 THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT DRUGS FOR FIRST-LINE THERAPY OF METASTATIC RENAL CELL CARCINOMA IN RUSSIA

    Nov 1, 2019, 00:00

  • PSU6 ECONOMIC IMPACT OF A VALIDATED INTRAOPERATIVE BLEEDING SCALE: A RETROSPECTIVE MULTICENTER REVIEW FROM THE US PROSCPECTIVE

    Nov 1, 2019, 00:00

  • PIH23 ECONOMIC BURDEN OF TRANSFUSION DEPENDENT THALASSAEMIA (TDT) PATIENT IN MALAYSIA: A SOCIETAL PERSPECTIVE

    Nov 1, 2019, 00:00

  • PSY50 PATIENT PREFERENCES FOR PATIENT-CENTERED HEALTHCARE IN THE TREATMENT OF HEMOPHILIA: A BEST-WORST SCALING CASE 3

    Nov 1, 2019, 00:00

  • PCN242 REDEFINING VALUE IN ONCOLOGY: APPLICATION OF MIXTURE CURE MODELS FOR ECONOMIC ANALYSES OF NOVEL THERAPIES FOR SMALL CELL LUNG CANCER (SCLC)

    Nov 1, 2019, 00:00

  • PRO94 EXPLORING POTENTIAL CLINICAL BENEFITS AND COST SAVINGS FROM IMPLEMENTING A STANDARDIZED DIGITAL REFERRAL PROCESS FOR DIAGNOSIS AND MANAGEMENT OF RARE DISEASES IN SPAIN: A CASE EXAMPLE FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

    Nov 1, 2019, 00:00

  • PCN459 DEVELOPMENT OF A PATIENT-CENTERED CONCEPTUAL MODEL DESCRIBING THE IMPACT OF LIVING WITH HEPATOCELLULAR CARCINOMA

    Nov 1, 2019, 00:00

  • PCN445 INDIRECT TREATMENT COMPARISON OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VERSUS TISAGENLECLEUCEL (TISA-CEL) IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (RR-LBCL)

    Nov 1, 2019, 00:00

  • PIN38 THE COST OF STIGMA ASSOCIATED WITH HIV: A COST-CONSEQUENCE ANALYSIS TO EVALUATE HIV TESTING AND PREVENTION INTERVENTIONS IN KSA

    Nov 1, 2019, 00:00

  • Individual's Health - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PDB17 HEALTH ECONOMIC EFFECTS OF THE UPDATED FOOT ULCER SUBMODEL IN THE IQVIA CORE DIABETES MODEL

    Nov 1, 2019, 00:00

  • PDB31 TRENDS IN THE USES OF ANTI-OSTEOPOROTIC DRUGS IN TAIWAN FROM 2012 TO 2018

    Nov 1, 2019, 00:00

  • PNS28 ADVANCING VALUE ASSESSMENTS: HOW CAN A PARADIGM OF VALUE MEASUREMENT BEYOND QALY BE ENHANCED TO HOLISTICALLY CAPTURE WHAT TRULY MATTERS TO PATIENTS AND PAYERS?

    Nov 1, 2019, 00:00

  • PCN226 THE COST-EFFECTIVENESS AND RELAPSE-REDUCTION BENEFIT OF INTRODUCING ADJUVANT NIVOLUMAB FOR PATIENTS WITH COMPLETELY WITH RESECTED MELANOMA WITH LYMPH NODE INVOLVEMENT OR METASTATIC DISEASE IN THE UK

    Nov 1, 2019, 00:00

  • PNS386 PATIENT PREFERENCES IN THE MEDICAL PRODUCT LIFECYCLE: INITIAL RESULTS FROM THE IMI PREFER PUBLIC-PRIVATE PROJECT

    Nov 1, 2019, 00:00

  • Injury Trauma - Medical Technologies

    Nov 1, 2019, 00:00

  • IN2 IMPACT OF TESTING RAPID INITIATION ON HIV INCIDENCE IN FRANCE: RESULTS OF A TRANSMISSION MODEL

    Nov 1, 2019, 00:00

  • PRO84 REGULATORY AND MARKET ACCESS LANDSCAPE FOR CYSTIC FIBROSIS

    Nov 1, 2019, 00:00

  • PNS242 BALANCING GLOBAL HTA REQUIREMENTS FOR LITERATURE REVIEWS ACROSS EUROPE, NORTH AMERICA, AND ASIA

    Nov 1, 2019, 00:00

  • PRO157 PREDICTING HEALTH UTILITIES FROM PATIENT-REPORTED OUTCOME MEASURES (PROMS) IN RARE DISEASES: A SYSTEMATIC REVIEW OF MAPPING STUDIES

    Nov 1, 2019, 00:00

  • PCN290 IMPLEMENTATION OF COMBINATION THERAPY PRICING RULES IN ONCOLOGY: LESSONS FROM MULTIPLE MYELOMA

    Nov 1, 2019, 00:00

  • PCN298 IMPROVED DRG-BASED REIMBURSEMENT OF ANTINEOPLASTIC PHARMACOTHERAPY AT RUSSIAN HOSPITALS

    Nov 1, 2019, 00:00

  • PNS317 FAILURE OR EFFECT: ATTRIBUTE FRAMING IN A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2019, 00:00

  • PRS11 EVIDENCE SYNTHESIS IN PULMONARY ARTERIAL HYPERTENSION: A CRITICAL APPRAISAL

    Nov 1, 2019, 00:00

  • PIN128 BUDGET IMPACT ANALYSIS OF CEFTAZIDIME/AVIBACTAM FOR THE TREATMENT OF ADULTS WITH COMPLICATED URINARY TRACT INFECTIONS IN BULGARIA

    Nov 1, 2019, 00:00

  • PND24 COST-EFFECTIVENESS ANALYSIS OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

    Nov 1, 2019, 00:00

  • PRO134 HEALTH-RELATED QUALITY OF LIFE IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT) PATIENTS IN EUROPE AND US: AN OBSERVATIONAL DISEASE REGISTRY

    Nov 1, 2019, 00:00

  • PCN446 A CASE STUDY OF BREAST CANCER TREATMENT DEMONSTRATING THE IMPACT OF TIME DEPENDENT TRANSITION PROBABILITY ADJUSTMENTS ON COMPARATIVE COST EFFECTIVENESS

    Nov 1, 2019, 00:00

  • PCV59 HOSPITAL LENGTH OF STAY AMONG VENOUS THROMBOEMBOLISM PATIENTS TREATED WITH APIXABAN AND WARFARIN IN ENGLAND

    Nov 1, 2019, 00:00

  • PNS399 DEVELOPMENT OF POPULATION TARIFFS FOR THE CARER-QOL-7D INSTRUMENT FOR HUNGARY, POLAND AND SLOVENIA: A DISCRETE CHOICE EXPERIMENT STUDY TO MEASURE THE BURDEN OF INFORMAL CAREGIVING

    Nov 1, 2019, 00:00

  • PBI17 BUDGET IMPACT ANALYSIS OF INTRAVENOUS BIOSIMILAR RITUXIMAB AND TRASTUZUMAB COMPARED TO INTRAVENOUS AND SUBCUTANEOUS ORIGINATORS IN FRANCE, GERMANY, ITALY, SPAIN, AND THE UK

    Nov 1, 2019, 00:00

  • PAM5 A SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF INTERVENTIONS WITH A PERSONALIZED NUTRITION COMPONENT IN ADULTS

    Nov 1, 2019, 00:00

  • PBI83 GOLIMUMAB IMPROVES QUALITY OF LIFE AND OTHER PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS, IN REAL-WORLD CONDITIONS

    Nov 1, 2019, 00:00

  • PCN507 CAN TRANSFERABILITY OF CLINICAL TRIALS POPULATION TO REAL WORLD SETTING BE ASSESSED USING FRENCH NATIONAL HEALTHCARE DATABASE? A CASE STUDY IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PCN360 SURROGATE ENDPOINT VALIDATION STUDIES SUBMITTED TO THE GERMAN HEALTH TECHNOLOGY ASSESSMENT AUTHORITY, THE FEDERAL JOINT COMMITTEE (G-BA). CASE STUDIES IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PND121 ANTIPSYCHOTICS UTILIZATION AND DIRECT MEDICAL COSTS ASSOCIATED WITH SCHIZOPHRENIA IN CHINESE PATIENTS

    Nov 1, 2019, 00:00

  • PIN58 ARE PUBLISHED HEALTH ECONOMIC MODELS FOR CHRONIC HEPATITIS B APPROPRIATELY CAPTURING THE BENEFITS OF HBSAG LOSS?

    Nov 1, 2019, 00:00

  • PSU3 ALTERATIONS IN PATIENT WEIGHT AND CLINICAL FACTORS FOLLOWING GASTRIC BYPASS SURGERY

    Nov 1, 2019, 00:00

  • Individual's Health - Economic Evaluation

    Nov 1, 2019, 00:00

  • PCN526 PHYSICIAN ACCEPTANCE OF REAL-WORLD EVIDENCE IN DRUG APPROVAL AND LABELING

    Nov 1, 2019, 00:00

  • PCN251 THE INCIDENCE OF SOFT TISSUE SARCOMA OVER THE NEXT TWO DECADES (2018-2040)

    Nov 1, 2019, 00:00

  • PND109 PATIENT PREFERENCE FOR DOSING REGIMEN AND PERCEPTION OF DOSING FLEXIBILITY WITH FREMANEZUMAB FOR CHRONIC OR EPISODIC MIGRAINE: RESULTS FROM A WEB-BASED, PATIENT SURVEY FOLLOWING COMPLETION OF A 1-YEAR EXTENSION STUDY

    Nov 1, 2019, 00:00

  • PIH3 VARIATIONS IN DURATION OF MECHANICAL VENTILATION IN VERY LOW BIRTH WEIGHT INFANTS IN JAPAN

    Nov 1, 2019, 00:00

  • PCN197 BUDGET IMPACT OF LUNG CANCER SCREENING WITH LOW-DOSE COMPUTERIZED TOMOGRAPHY FOR SMOKING GROUPS

    Nov 1, 2019, 00:00

  • PBI58 RESISTANCE TO OR SUPPORT OF BIOSIMILARS' MARKET PENETRATION? A SYSTEMATIC REVIEW OF EUROPEAN STAKEHOLDERS' BEHAVIOURS

    Nov 1, 2019, 00:00

  • PNS79 DETERMINING THE BASELINE STRATEGY IN A COST-EFFECTIVENESS ANALYSIS WITH TREATMENT SEQUENCES

    Nov 1, 2019, 00:00

  • PRO91 UTILITY OF REAL WORLD EVIDENCE DATA TO SUPPORT MARKET ACCESS OF RARE ONCOLOGY INDICATIONS IN EU5

    Nov 1, 2019, 00:00

  • Multiple Diseases - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PIH33 FREQUENCY AND NATURE OF INPATIENT TREATMENT OF MULTIPLE OSTEOCHONDROMA (MO) IN GERMANY FROM 2005 TO 2016

    Nov 1, 2019, 00:00

  • A Real-World Evidence Analysis of Associations Among Costs, Quality of Life, and Disease-Severity Indicators of Alzheimer’s Disease in Thailand

    Oct 1, 2019, 00:00

  • Risk of Dependency: A Challenge for Health and Social Care Planning--Observational Stroke Cohort

    Oct 1, 2019, 00:00

  • A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management [Editor's Choice]

    Oct 1, 2019, 00:00

  • Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier

    Oct 1, 2019, 00:00

  • A Cost Analysis and Cost-Utility Analysis of a Community Pharmacist–Led Intervention on Reducing Cardiovascular Risk: The Alberta Vascular Risk Reduction Community Pharmacy Project (RxEACH)

    Oct 1, 2019, 00:00

  • Estimators Used in Multisite Healthcare Costing Studies in Low- and Middle-Income Countries: A Systematic Review and Simulation Study

    Oct 1, 2019, 00:00

  • Psychometric Properties of EQ-5D-5L Scoring Algorithms for the United Kingdom in Metastatic Merkel Cell Carcinoma

    Oct 1, 2019, 00:00

  • Table of Contents

    Oct 1, 2019, 00:00

  • A Comparison of National Guidelines for Network Meta-Analysis

    Oct 1, 2019, 00:00

  • Choosing Video Instead of In-Clinic Consultations in Primary Care in Israel: Discrete Choice Experiment Among Key Stakeholders—Patients, Primary Care Physicians, and Policy Makers

    Oct 1, 2019, 00:00

  • On the Optimization of Bayesian D-Efficient Discrete Choice Experiment Designs for the Estimation of QALY Tariffs That Are Corrected for Nonlinear Time Preferences [Editor's Choice]

    Oct 1, 2019, 00:00

  • Copyright/Subscription

    Oct 1, 2019, 00:00

  • External Validation of a Colorectal Cancer Model Against Screening Trial Long-Term Follow-Up Data

    Oct 1, 2019, 00:00

  • Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice

    Oct 1, 2019, 00:00

  • Implementing Patient-Reported Outcome Measures in Clinical Breast Cancer Care: A Systematic Review [Editor's Choice]

    Oct 1, 2019, 00:00

  • Cost-Effectiveness Analysis of a Mobile Mammography Unit for Breast Cancer Screening to Reduce Geographic and Social Health Inequalities

    Oct 1, 2019, 00:00

  • Editorial Board

    Sep 26, 2019, 08:53

  • Copyright/Subscription

    Sep 9, 2019, 08:11

  • Yes, Improve the US Value Frameworks, But Recognize They Are Already in Prime Time

    Sep 1, 2019, 00:00

  • A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions

    Sep 1, 2019, 00:00

  • Estimating the Marginal Productivity of the English National Health Service From 2003 to 2012

    Sep 1, 2019, 00:00

  • Something Is Better Than Nothing: The Value of Active Intervention in Stated Preferences for Treatments to Delay Onset of Alzheimer's Disease Symptoms

    Sep 1, 2019, 00:00

  • Are Healthcare Choices Predictable? The Impact of Discrete Choice Experiment Designs and Models [Editor's Choice]

    Sep 1, 2019, 00:00

  • Evaluation of the Association Between Health State Utilities and Obesity in Sub-Saharan Africa: Evidence From World Health Organization Study on Global AGEing and Adult Health Wave 2

    Sep 1, 2019, 00:00

  • Barriers and Facilitators to Model Replication Within Health Economics [Editor's Choice]

    Sep 1, 2019, 00:00

  • Expert Elicitation to Inform a Cost-Effectiveness Analysis of Screening for Renal Cancer

    Sep 1, 2019, 00:00

  • Adjusting for Inflation and Currency Changes Within Health Economic Studies

    Sep 1, 2019, 00:00

  • Editorial Board

    Sep 1, 2019, 00:00

  • Value of the Rare Disease Registry of the Italian Region Friuli Venezia Giulia

    Sep 1, 2019, 00:00

  • As Value Assessment Frameworks Evolve, Are They Finally Ready for Prime Time? [Editor's Choice]

    Sep 1, 2019, 00:00

  • Development and Psychometric Validation of an Instrument to Identify Barriers to Self-Care Among Spanish Patients With Type 2 Diabetes on the Basis of Theory of Planned Behavior

    Sep 1, 2019, 00:00

  • Table of Contents

    Sep 1, 2019, 00:00

  • Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy

    Sep 1, 2019, 00:00

  • Extrapolating Survival Data Using Historical Trial–Based a Priori Distributions

    Sep 1, 2019, 00:00

  • Editorial Board

    Aug 16, 2019, 09:04

  • A Microsimulation Model for Evaluating the Effectiveness of Cancer Risk Management for BRCA Pathogenic Variant Carriers: miBRovaCAre

    Aug 1, 2019, 00:00

  • Symptoms of Major Depressive Disorder Scale: Performance of a Novel Patient-Reported Symptom Measure

    Aug 1, 2019, 00:00

  • Cost-Effectiveness of Cryoballoon Ablation Versus Radiofrequency Ablation for Paroxysmal Atrial Fibrillation in China: Results Based on Real-World Data

    Aug 1, 2019, 00:00

  • United States Valuation of EQ-5D-5L Health States Using an International Protocol

    Aug 1, 2019, 00:00

  • Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip Replacement: A Systematic Review and Network Meta-Analysis

    Aug 1, 2019, 00:00

  • PROM Validation Using Paper-Based or Online Surveys: Data Collection Methods Affect the Sociodemographic and Health Profile of the Sample

    Aug 1, 2019, 00:00

  • When Opportunity Knocks, What Does It Say?

    Aug 1, 2019, 00:00

  • Selection of Endpoints in Clinical Trials: Trends in European Marketing Authorization Practice in Oncological Indications

    Aug 1, 2019, 00:00

  • A Scoping Review of Investment Cases for Vaccines and Immunization Programs

    Aug 1, 2019, 00:00

  • Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment [Editor's Choice]

    Aug 1, 2019, 00:00

  • Patient-Reported Outcomes in Orphan Drug Labels Approved by the US Food and Drug Administration [Editor's Choice]

    Aug 1, 2019, 00:00

  • An Ethical Analysis of Coverage With Evidence Development [Editor's Choice]

    Aug 1, 2019, 00:00

  • Table of Contents

    Aug 1, 2019, 00:00

  • Implications of Nonmarginal Budgetary Impacts in Health Technology Assessment: A Conceptual Model

    Aug 1, 2019, 00:00

  • Important Considerations in Modeling the Cost-Effectiveness for the First Food and Drug Administration–Approved Gene Therapy and Implications for Future One-Time Therapies

    Aug 1, 2019, 00:00

  • Author Reply

    Aug 1, 2019, 00:00

  • Copyright/Subscription

    Aug 1, 2019, 00:00

  • Per-Prescription Drug Expenditure by Source of Payment and Income Level in the United States, 1997 to 2015 [Editor's Choice]

    Aug 1, 2019, 00:00

  • Normative Profile of Health-Related Quality of Life for Hong Kong General Population Using Preference-Based Instrument EQ-5D-5L

    Aug 1, 2019, 00:00

  • Editorial Board

    Jul 2, 2019, 09:19

  • Time-Driven Activity-Based Costing in Urologic Surgery Cycles of Care

    Jul 1, 2019, 00:00

  • Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States

    Jul 1, 2019, 00:00

  • Consistency Between Three Different Ways of Administering the Short Form 6 Dimension Version 2

    Jul 1, 2019, 00:00

  • How Prevalent Are Implausible EQ-5D-5L Health States and How Do They Affect Valuation? A Study Combining Quantitative and Qualitative Evidence

    Jul 1, 2019, 00:00

  • Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory? [Editor's Choice]

    Jul 1, 2019, 00:00

  • How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma

    Jul 1, 2019, 00:00

  • Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing–Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study

    Jul 1, 2019, 00:00

  • Parent Proxy Discrepancy Groups of Quality of Life in Childhood Epilepsy

    Jul 1, 2019, 00:00

  • Cancer History, Health Insurance Coverage, and Cost-Related Medication Nonadherence and Medication Cost-Coping Strategies in the United States

    Jul 1, 2019, 00:00

  • The Corrective Approach: Policy Implications of Recent Developments in QALY Measurement Based on Prospect Theory

    Jul 1, 2019, 00:00

  • Evolving Use of Real-World Evidence for Devices: Good for Patients, Good for Policy Makers

    Jul 1, 2019, 00:00

  • Machine Learning for Health Services Researchers [Editor's Choice]

    Jul 1, 2019, 00:00

  • Table of Contents

    Jul 1, 2019, 00:00

  • Reconciling the Seemingly Irreconcilable: How Much Are We Spending on Drugs?

    Jul 1, 2019, 00:00

  • A New Method to Determine the Optimal Willingness to Pay in Cost-Effectiveness Analysis

    Jul 1, 2019, 00:00

  • ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products

    Jul 1, 2019, 00:00

  • Copyright/Subscription

    Jul 1, 2019, 00:00

  • Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States

    Jun 1, 2019, 00:00

  • A Beginner's Guide to Understanding Curative Therapies

    Jun 1, 2019, 00:00

  • New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare—An Introduction

    Jun 1, 2019, 00:00

  • Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy [Editor's Choice]

    Jun 1, 2019, 00:00

  • Patient Preferences for Endometriosis Pain Treatments in the United States

    Jun 1, 2019, 00:00

  • Defining and Managing High-Priced Cures: Healthcare Payers’ Opinions

    Jun 1, 2019, 00:00

  • Effect of Health State Sampling Methods on Model Predictions of EQ-5D-5L Values: Small Designs Can Suffice

    Jun 1, 2019, 00:00

  • Table of Contents

    Jun 1, 2019, 00:00

  • Meaningful and Measurable Health Domains in Huntington’s Disease: Large-Scale Validation of the Huntington’s Disease Health-Related Quality of Life Questionnaire Across Severity Stages

    Jun 1, 2019, 00:00

  • Development and Validation of the MiPrep Survey: An Instrument Assessing Patients' Perceived Preparation for Medical Interventions Including Medical Imaging, Radiotherapy, and Surgery

    Jun 1, 2019, 00:00

  • Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment?

    Jun 1, 2019, 00:00

  • Current Value Frameworks—What's New?

    Jun 1, 2019, 00:00

  • A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus

    Jun 1, 2019, 00:00

  • Valuing Health Status in the First Year of Life: The Infant Health-Related Quality of Life Instrument

    Jun 1, 2019, 00:00

  • Current Policy and Practice for Value-Based Pricing

    Jun 1, 2019, 00:00

  • Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America

    Jun 1, 2019, 00:00

  • Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System [Editor's Choice]

    Jun 1, 2019, 00:00

  • Specific Value Assessment Considerations

    Jun 1, 2019, 00:00

  • Copyright/Subscription

    Jun 1, 2019, 00:00

  • Are Global Health Systems Ready for Transformative Therapies?

    Jun 1, 2019, 00:00

  • Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies? [Editor's Choice]

    Jun 1, 2019, 00:00

  • Novel Approaches to Value Assessment Within the Cost-Effectiveness Framework

    Jun 1, 2019, 00:00

  • Guide for Authors

    Jun 1, 2019, 00:00

  • Editorial Board

    Jun 1, 2019, 00:00

  • Novel Approaches to Value Assessment Beyond the Cost-Effectiveness Framework

    Jun 1, 2019, 00:00

  • How Does Treating Chronic Hepatitis C Affect Individuals in Need of Organ Transplants in the United Kingdom?

    Jun 1, 2019, 00:00

  • New Cost-Effectiveness Methods to Determine Value-Based Prices for Potential Cures: What Are the Options? [Editor's Choice]

    Jun 1, 2019, 00:00

  • Practical Next Steps in Improving Value Measurement and Use

    Jun 1, 2019, 00:00

  • Comparing the Noncomparable: The Need for Equivalence Measures That Make Sense in Health-Economic Evaluations [Editor's Choice]

    Jun 1, 2019, 00:00

  • Editorial Board

    May 17, 2019, 08:37

  • Diabetes/Endocrine/Metabolic Disorders - Methodological Statistical Research

    May 1, 2019, 00:00

  • PNS115 ASSOCIATION BETWEEN THE AFFORDABLE CARE ACT (ACA) AND REDUCED DISPARITIES IN ACCESS TO CARE BY ENGLISH LANGUAGE PROFICIENCY AMONG HISPANIC ADULTS

    May 1, 2019, 00:00

  • Musculoskeletal Disorders - Epidemiology Public Health

    May 1, 2019, 00:00

  • PDG20 COST-EFFECTIVENESS ANALYSIS OF EZETIMIBE AS THE ADD-ON TREATMENT TO MODERATE-DOSE ROSUVASTATIN VERSUS HIGH-DOSE ROSUVASTATIN IN THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN CHINA: A MARKOV MODEL ANALYSIS BASED ON NSTE-ACS

    May 1, 2019, 00:00

  • PMD30 HOSPITAL RELATED CLINICAL AND ECONOMICAL OUTCOMES OF TWO PREMIUM KNEE SYSTEM IN TOTAL KNEE ARTHROPLASTY PATIENTS

    May 1, 2019, 00:00

  • PNS158 ARE THE PRIMARY HEALTH CENTERS ADEQUATELY EQUIPPED TO DELIVER PRIMARY HEALTHCARE IN INDIA? A STUDY OF PUBLIC HEALTH MANPOWER AND INFRASTRUCTURE

    May 1, 2019, 00:00

  • PIH19 A SYSTEMATIC REVIEW OF PHARMACOECONOMIC LITERATURE SCORING TOOLS FOR STUDIES ON HORMONAL CONTRACEPTIVES

    May 1, 2019, 00:00

  • PMH38 INCREASING PREVALENCE OF DEPRESSION AND THE ASSOCIATED RISK FACTORS IN THE US: A STUDY BASED ON NHANES FROM 2005 TO 2016

    May 1, 2019, 00:00

  • Injury Trauma - Clinical Outcomes

    May 1, 2019, 00:00

  • PIN36 A COST CONSEQUENCE MODEL TO EVALUATE THE IMPACT OF BLOOD CULTURE TECHNOLOGY AND BEST PRACTICES ON SEPSIS MANAGEMENT

    May 1, 2019, 00:00

  • Injury Statistical Research

    May 1, 2019, 00:00

  • NO Specific Disease - Conceptual Papers (CP)

    May 1, 2019, 00:00

  • PCN281 KNOWLEDGE OF PALLIATIVE CARE AMONG AMERICAN ADULTS: 2018 HEALTH INFORMATION NATIONAL TRENDS SURVEY

    May 1, 2019, 00:00

  • PIH35 ECONOMIC BURDEN FOR PEDIATRIC PATIENTS WITH RELAPSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN THE US

    May 1, 2019, 00:00

  • PND75 PROMIS-PREFERENCE SCORES ARE ASSOCIATED WITH UTILIZATION IN OUTPATIENT NEUROLOGY PATIENTS

    May 1, 2019, 00:00

  • PDG22 A DECISION ANALYSIS OF ADDING ANGIOTENSIN II TO RENAL REPLACEMENT THERAPY TO TREAT PATIENTS WITH ACUTE KIDNEY INJURY AND VASODILATORY SHOCK

    May 1, 2019, 00:00

  • PNS2 APPLICATION OF MACHINE LEARNING TECHNIQUES IN OUTCOMES RESEARCH: A REVIEW

    May 1, 2019, 00:00

  • PNS223 A BIBLIOMETRICS ANALYSIS OF COST-CONSEQUENCE ANALYSIS USED IN ECONOMICAL EVALUATIONS

    May 1, 2019, 00:00

  • PNS19 AN APPROACH TO EXAMINING GEOGRAPHIC VARIATION IN HEALTHCARE SPENDING AND UTILIZATION IN THE CANADIAN WORKERS COMPENSATION SYSTEM

    May 1, 2019, 00:00

  • PDG55 INDEX OF INSTABILITY OF THE DEMAND OF TECHNOLOGIES IN RELEVANT MARKETS OF CONTRACEPTIVES

    May 1, 2019, 00:00

  • Drugs Process of Care

    May 1, 2019, 00:00

  • PCN270 DEVELOPING A PATIENT-REPORTED OUTCOME MEASURE TO CAPTURE ADVERSE EVENTS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

    May 1, 2019, 00:00

  • PMD34 COMPARISON OF MEDICAL RESOURCE UTILIZATION AND COSTS BETWEEN PATIENTS WITH EARLY POSTOPERATIVE PERIPROSTHETIC HIP FRACTURES AND THOSE WITHOUT FOLLOWING TOTAL HIP ARTHROPLASTY: A MULTILEVEL MATCHED ANALYSIS

    May 1, 2019, 00:00

  • PNS193 MODELING ADOPTION AND OPTIMIZATION OF AUTOMATION SUPPLY CHAIN MANAGEMENT TECHNOLOGY WITH RFID (UHF) IN THE US ACUTE HOSPITAL SETTING

    May 1, 2019, 00:00

  • PND90 REAL WORLD REPLICATION OF CLINICAL TRIAL FINDINGS IN ALZHEIMER'S DISEASE

    May 1, 2019, 00:00

  • PCN292 STUDY ON PHYSICIANS' PREFERENCE FOR TREATMENT OF NSCLC IN WESTERN CHINA

    May 1, 2019, 00:00

  • PCN238 CANCER PATIENT ENGAGEMENT IN 2018 - COMMUNITY PROVIDERS PERSPECTIVES ON DIGITAL DATA AND COMMUNICATION AT THE BEDSIDE

    May 1, 2019, 00:00

  • Table of Contents

    May 1, 2019, 00:00

  • PND50 PRESCRIPTION PATTERN OF ANTICHOLINERGIC DRUGS IN ALZHEIMER'S DISEASE

    May 1, 2019, 00:00

  • PND56 USE OF IPRATROPIUM AND SALMETEROL MIGHT REDUCE THE RISK OF MULTIPLE SCLEROSIS (MS)

    May 1, 2019, 00:00

  • PNS178 CONSUMER HEALTH INFORMATION TECHNOLOGY IN THE PREVENTION OF SUBSTANCE ABUSE: A SCOPING REVIEW

    May 1, 2019, 00:00

  • PDB9 FACTORS ASSOCIATED WITH AND IMPLICATIONS OF MEETING OR NOT MEETING HBA1C TARGETS IN TYPE 2 DIABETES MELLITUS

    May 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Conceptual Papers (CP)

    May 1, 2019, 00:00

  • PMU19 EVALUATION OF THE COSTS OF A COMPREHENSIVE ONE HEALTH PREPAREDNESS INTERVENTION PROGRAM IN 3 DISTRICTS IN UGANDA'S WEST NILE REGION

    May 1, 2019, 00:00

  • PMU113 THE COST OF MEDICAL TELECONSULTATIONS OF A BRAZILIAN GOVERNMENT EHEALTH SERVICE

    May 1, 2019, 00:00

  • PMH62 AN ASSESSMENT OF THE HUMANISTIC IMPACT OF SCHIZOPHRENIA IN RELATION TO CAREGIVER AND PRODUCTIVITY BURDEN

    May 1, 2019, 00:00

  • PNS30 CAN AYUSHMANN BHARAT ALTER INDIA'S HEALTHCARE LANDSCAPE?

    May 1, 2019, 00:00

  • PND16 A RETROSPECTIVE CLAIMS ANALYSIS OF US HEALTH PLAN COMMERCIAL INSURANCE DATA ASSESSING HEALTHCARE COSTS AND RELAPSE RATES IN MULTIPLE SCLEROSIS PATIENTS TREATED WITH GENERIC GLATIRAMER ACETATE

    May 1, 2019, 00:00

  • PIH31 COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AS A SECOND-LINE THERAPY IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CHINA

    May 1, 2019, 00:00

  • PNS231 THE VALUE OF EMBEDDED INTERVIEWS: CASE STUDY OF QUALITATIVE AND QUANTITATIVE ASSESSMENT OF THE PATIENT EXPERIENCE OF MEPOLIZUMAB SELF-ADMINISTRATION

    May 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Medical Technologies

    May 1, 2019, 00:00

  • PDB121 EVALUATING INTERVENTION TRAJECTORIES OF STATIN ADHERENCE FOLLOWING A MOTIVATIONAL-INTERVIEWING INTERVENTION CUSTOMIZED BY PAST ADHERENCE TRAJECTORIES TO IMPROVE STATIN ADHERENCE

    May 1, 2019, 00:00
  • «
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57 (current)
  • 58
  • 59
  • 60
  • »